|
 LSN is proud to announce the RESI Partnering Platform. The goal is to have a dynamic partnering platform to match biotech and medtech companies with the investors that are a fit and provide an opportunity to create a compelling dialogue that fosters a long-term relationship. LSN designed the RESI Partnering Platform from the ground up by leveraging an innovative partnering portal provider called Meeting Mojo.
Click the video below to see how the RESI Partnering Platform can help your partnering efforts.
 | |
Click here to view the RESI Partnering Platform demo
|
|
|
By Michael Quigley, Director of Research, LSN
Just over a year ago I published an article discussing how the growth rate of seed and startup stage life science financing rounds was substantially smaller than all other financing rounds. More recent data pulled from the LSN's Company Platform further validates that claim. Exhibit 1 compares the number of seed and startup stage financing rounds to the total number of financings in the US life science space over the past 9 years...
|
 A New Model for Foundations: Non-Profit to For-Profit PanelIn the past, non-profit organizations dedicated to research in specific disease areas were typically unable to take advantage of the upside of any significant discoveries that were funded through their organization. Recently, a new trend has emerged: non-profit organizations investing in early stage biotech/medtech companies in return for equity. This new way of investing provides the foundation the ability to reinvest their profits, providing additional capital to fund future research.
Moderated by David Sandak, Vice President, Research at Accelerate Brain Cancer Cure, the audience will hear from:
- Howard Fillit, Executive Director and Chief Science Officer, Alzheimer's Drug Discovery Fund
- Benjamin Seckler, Founder and President, Charley's Fund
- Annette Bakker, President & CSO, Children's Tumor Foundation
- Keting Chu, VP, Research TAP, Leukemia & Lymphoma Society (LLS)
|
Life Science Investor Mandates 
